US · ATR
AptarGroup, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Crystal Lake, IL 60014
- Website
- aptar.com
Price · as of 2025-12-31
$119.02
Market cap 9.43B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $98.84 | -16.96% |
| Intrinsic Value(DCF) | $58.29 | -51.03% |
| Graham-Dodd Method(GD) | $26.50 | -77.73% |
| Graham Formula(GF) | $79.44 | -33.25% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $43.74 | $59.97 | $1.64 | $17.65 | $55.70 |
| 2012 | $45.95 | $50.21 | $0.24 | $14.53 | $19.45 |
| 2013 | $55.58 | $55.02 | $0.00 | $14.96 | $41.57 |
| 2014 | $54.30 | $51.22 | $3.14 | $10.24 | $32.43 |
| 2015 | $66.36 | $66.12 | $5.08 | $12.26 | $0.00 |
| 2016 | $68.35 | $59.01 | $4.89 | $10.26 | $28.49 |
| 2017 | $82.09 | $78.40 | $5.49 | $12.31 | $48.88 |
| 2018 | $92.02 | $66.66 | $1.06 | $7.19 | $61.16 |
| 2019 | $99.48 | $78.11 | $0.00 | $10.48 | $43.37 |
| 2020 | $132.07 | $93.71 | $0.00 | $9.81 | $34.64 |
| 2021 | $106.60 | $74.96 | $0.00 | $11.24 | $66.49 |
| 2022 | $108.37 | $76.62 | $0.00 | $12.43 | $40.25 |
| 2023 | $139.56 | $86.60 | $0.01 | $18.45 | $55.99 |
| 2024 | $150.75 | $104.23 | $0.00 | $25.59 | $61.03 |
| 2025 | $142.67 | $98.84 | $3.76 | $26.50 | $79.44 |
AI valuation
Our deep-learning model estimates AptarGroup, Inc.'s (ATR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $98.84
- Current price
- $119.02
- AI upside
- -16.96%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$58.29
-51.03% upside
Graham-Dodd
$26.50
-77.73% upside
Graham Formula
$79.44
-33.25% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ATR | AptarGroup, Inc. | $119.02 | 9.43B | -17% | -51% | -78% | -33% | 23.88 | 3.52 | 2.48 | 12.63 | 366.80 | 7.03 | 29.58% | 13.53% | 10.40% | 15.28% | 11.48% | 8.11% | 0.57 | 9.69 | 1.62 | 1.04 | 1.36 | 651.00% | 542.00% | -1422.00% | 3.19% | 0.49 | 8.43% | 1.29% | 30.80% | 5.18% | 20.55 | 35.05 | 2.78 | 4.13 |
| AVTR | Avantor, Inc. | $9.05 | 6.17B | +191% | -61% | — | — | -11.27 | 1.07 | 0.91 | 68.88 | — | -2.28 | 32.65% | -3.76% | -8.09% | -9.20% | -2.61% | -4.44% | 0.71 | -1.45 | 1.78 | 1.04 | 25.82 | -17500.00% | -341.00% | -2847.00% | 8.29% | 0.45 | 5.24% | 0.00% | 0.00% | 4.92% | -38.81 | 19.30 | 1.46 | 1.37 |
| GMED | Globus Medical, Inc. | $95.46 | 12.89B | +11% | +76% | -55% | 0% | 23.57 | 2.77 | 4.31 | 16.77 | 5.58 | 5.30 | 67.41% | 16.33% | 18.30% | 12.29% | 10.63% | 10.19% | 0.03 | — | 4.26 | 2.48 | -0.56 | 42267.00% | 1665.00% | 4530.00% | 4.64% | 1.51 | 14.79% | 0.00% | 0.00% | 3.63% | 25.51 | 20.79 | 4.16 | 12.01 |
| GRFS | Grifols, S.A. | $9.10 | 7.7B | +209% | -64% | — | -49% | 10.85 | 0.82 | 0.67 | 9.37 | 6.98 | -1.08 | 38.75% | 16.53% | 2.18% | 7.89% | 3.72% | 2.09% | 1.71 | 1.54 | 2.66 | 0.96 | 6.13 | 15556.00% | 941.00% | -67929.00% | 11.02% | 0.42 | 3.46% | 0.02% | 0.20% | 28.68% | 11.66 | 26.19 | 1.93 | 0.96 |
| HALO | Halozyme Therapeutics, In… | $69.53 | 8.21B | +26% | +70% | -87% | +68% | 26.42 | 171.48 | 5.99 | 9.10 | — | -5.53 | 78.13% | 58.45% | 22.69% | 153.59% | 93.94% | 13.81% | 0.00 | 45.03 | 4.66 | 3.30 | -0.15 | -2536.00% | 3755.00% | 3762.00% | 7.70% | 3.68 | 109.29% | 0.00% | 0.00% | 22.29% | 10.08 | 12.76 | 5.89 | 3.99 |
| HSIC | Henry Schein, Inc. | $82.39 | 9.99B | +2% | -60% | -90% | -52% | 24.70 | 3.03 | 0.75 | 13.28 | 342.43 | -4.95 | 29.14% | 5.75% | 3.02% | 11.99% | 9.02% | 3.71% | 1.14 | 5.05 | 1.38 | 0.56 | 3.51 | 721.00% | 403.00% | -1331.00% | 5.83% | 0.22 | 8.87% | 0.00% | 0.00% | 8.65% | 17.63 | 23.32 | 1.01 | 2.86 |
| MASI | Masimo Corporation | $175.35 | 9.42B | — | -60% | — | -71% | -62.06 | 13.04 | 6.16 | 31.37 | — | 16.55 | 61.90% | 20.30% | -9.92% | — | — | — | 0.72 | — | 2.49 | 1.40 | 1.17 | — | — | — | 2.10% | 0.58 | — | 0.00% | 0.00% | 3.87% | 31.51 | 49.38 | 6.40 | 8.77 |
| MOH | Molina Healthcare, Inc. | $154.05 | 7.93B | +43% | +423% | -46% | +17% | 16.40 | 1.90 | 0.17 | 7.63 | — | 4.13 | 8.97% | 1.72% | 1.04% | 11.02% | 52.20% | 3.03% | 0.97 | 4.07 | 1.69 | 1.06 | -0.31 | -5632.00% | 1175.00% | -21691.00% | -8.21% | -0.07 | -53.04% | 0.00% | 0.00% | 12.92% | 9.53 | -11.70 | 0.16 | 4.20 |
| RGEN | Repligen Corporation | $128.73 | 7.25B | -26% | -60% | -83% | -84% | 143.73 | 3.34 | 9.52 | 42.30 | — | 11.60 | 47.09% | 8.07% | 6.62% | 2.40% | 2.38% | 1.69% | 0.33 | 2.57 | 8.37 | 6.82 | 0.75 | -28696.00% | 1636.00% | -3410.00% | 1.34% | 0.86 | 4.78% | 0.00% | 0.00% | 0.00% | 116.65 | 74.02 | 9.41 | 5.94 |
| STVN | Stevanato Group S.p.A. | $15.52 | 4.24B | +118% | -45% | -52% | -68% | 31.27 | 3.57 | 4.54 | 21.56 | — | 3.80 | 27.38% | 14.60% | 10.67% | 12.64% | 7.41% | 7.29% | 0.31 | 23.48 | 1.84 | 1.32 | 1.33 | -2182.00% | 172.00% | -5314.00% | -3.15% | 0.33 | -9.88% | 0.29% | 9.00% | 0.29% | 33.16 | -33.86 | 4.84 | 4.68 |
| TFX | Teleflex Incorporated | $122.06 | 5.39B | -20% | -55% | — | +315% | -6.06 | 1.76 | 2.75 | 17.49 | — | -7.79 | 56.24% | 2.94% | -45.45% | -24.47% | 1.35% | -12.90% | 0.06 | 0.58 | 2.54 | 0.95 | -0.64 | -146824.00% | -3461.00% | -9972.00% | 0.03% | 0.13 | 0.03% | 1.10% | -6.70% | 36.82% | 90.40 | 3659.08 | 2.66 | 2.01 |
About AptarGroup, Inc.
AptarGroup, Inc. provides a range of dispensing, sealing, and material science solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active material science solutions. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. It sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. The company has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
- CEO
- Stephan Tanda
- Employees
- 13K
- Beta
- 0.48
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($58.29 ÷ $119.02) − 1 = -51.03% (DCF, example).